B
Biond Biologics
Biotech & Life Sciences · Misgav Am, Israel · Founded 2016
Innovative immunotherapies and a pioneering intracellular delivery for biologics for the treatment of patients MoreLess
Biond Biologics is a biotechnology company focused on developing innovative therapies for novel oncology targets. The company operates in the biopharmaceutical market, aiming to uncover immunoregulatory pathways and enable the intracellular delivery of biologics. Biond Biologics serves clients in the pharmaceutical and healthcare sectors, including global pharma companies through collaborations and partnerships. The business model revolves around research and development (R&D) of proprietary technology platforms and novel therapeutic agents, such as BND-22, a macrophage activator currently in IND-enabling studies. The company generates revenue through strategic partnerships, licensing agreements, and financing rounds, including a completed Series B financing with participation from global biopharma companies. Biond Biologics has established a sustainable R&D hub in the Galilee, Israel, and continues to advance its pipeline of oncology therapies through rigorous proof-of-concept studies and clinical trials.
Keywords: oncology, immunotherapy, biologics, intracellular delivery, macrophage activator, R&D, partnerships, biotech, IND studies, Galilee.
Company overview
Biond Biologics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2016
- Headquarters
- Misgav Am, Israel
- Employees
- 35
- Open positions
- None listed
- Dealroom signal
- 30.9
Valuation & funding
Biond Biologics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Jun 2026 | $8M | $85M | Guangzhou Industrial Investment Fund | ↗ |
| SERIES C✓Equity / VC | Nov 2021 | $15M | $85M | Heritage Group · Deep Insight · Harel Group | — |
| SERIES B✓Equity / VC | Jan 2019 | $17M | $68M | SBI JI Innovation Fund · Celgene · Israel Biotech Fund · Harel Group | ↗ |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 35 |
| 2025 | 36 |
| 2024 | 43 |
| 2023 | 34 |
| 2022 | 31 |
| 2021 | 24 |
Growth signals
Biond Biologics website traffic
Latest recorded traffic for Biond Biologics is 320 monthly website visits, up 255.6% over the last three months. Biond Biologics's team declined 2.8% over the past year.
Comparisons
Biond Biologics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Biond Biologics's talent
Source: Dealroom Talent Intelligence.
Investors
8 investors on Biond Biologics's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Biond Biologics has talent and traffic
team presence
In the news
Latest news about Biond Biologics
Recent press, funding announcements, and product moves mentioning Biond Biologics — open to read from the original sources.
Market sentiment
What the market is saying about Biond Biologics
An AI-synthesized read of the highest-engagement posts about Biond Biologics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Biond Biologics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.